Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile

被引：0
|
作者：
Stepan, J. J.
Kendler, D.
Sedarati, F.
Burdeska, A.
Hughes, C.
Lorenc, R.
机构：
[1] Univ Prague, Prague, Czech Republic
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[5] Childrens Mem Inst, Warsaw, Poland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：429 / 429
页数：1
相关论文
共 50 条
  • [1] Once-monthly oral ibandronate is at least as effective as daily oral ibandronate in postmenopausal osteoporosis: 2-year findings from MOBILE.
    McClung, MR
    Drezner, MK
    Reginster, JY
    Bolognese, M
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [2] Once-monthly and daily oral ibandronate are similarly well tolerated in women with postmenopausal osteoporosis: 2-year results from mobile
    Luckey, M.
    Stepan, J.
    Kendler, D. L.
    Feldman, D.
    Lipschitz, S.
    Leigh, C.
    Burdeska, A.
    Hiltbrunner, V
    Morales-Torres, J.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S234
  • [3] Once-monthly oral ibandronate in postmenopausal osteoporosis: Mobile 2-year safety and tolerability analysis
    Felsenberg, D.
    Stone, M.
    Zikan, V.
    Hughes, C.
    Burdeska, A.
    Minic, B.
    Cooper, C.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S67 - S67
  • [4] Response to once-monthly and daily oral ibandronate in the mobile study: 2-year analysis
    不详
    CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S145 - S145
  • [5] Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE.
    Recker, RR
    Luckey, M
    Stakkestad, JA
    Civitelli, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [6] Once-monthly oral ibandronate is safe and well tolerated in women with postmenopausal osteoporosis: MOBILE 2-year analysis.
    Lewiecki, EM
    Emkey, R
    Adami, S
    Rowell, L
    Mairon, N
    Bonvoisin, B
    Felsenberg, D
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S285 - S285
  • [7] Once-monthly oral ibandronate - Effective treatment for postmenopausal osteoporosis (PMO): MOBILE 2-year results
    Miller, P
    Drezner, M
    Lewiecki, M
    Bolognese, M
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 803 - 803
  • [8] Influence of baseline patient characteristics on response to once-monthly and daily oral ibandronate therapy: 2-year findings from mobile
    Reginster, J. Y.
    Hawker, G.
    Bolognese, M.
    Coutant, K.
    Hughes, C.
    Sedarati, F.
    Stone, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 426 - 426
  • [9] Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE
    Silverman, S
    Greenwald, M
    Hawker, G
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Reginster, JY
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S735 - S736
  • [10] Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE.
    Greenwald, M
    Hawker, G
    Cooper, C
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Silverman, S
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S297 - S297
12345